Description

• General description: A Certified Solution Standard for use in LC or GC applications from forensic and forensic toxicology analysis to urine drug testing. N-Desmethylclobazam, found in urine, serum, and plasma, is the pharmacologically active, major metabolite of clobazam.
• Application: Impact on bioavailability in epilepsy treatment: A study discussed the implications of N-Desmethylclobazam on drug to drug interactions and neuropsychological impact when used as add-on therapy in drug-resistant epilepsies, highlighting its role in enhancing therapeutic bioavailability (Pietrafusa et al., 2023).Research on pharmacokinetic variability: Research explored the pharmacokinetic variability of N-Desmethylclobazam, emphasizing its influence by age, drug interactions, and biochemical markers of toxicity in patients with epilepsy, contributing to a deeper understanding of its pharmacological properties (Heger et al., 2024).Evaluation of drug-drug interactions: A comprehensive analysis investigated potential drug-drug interactions between N-Desmethylclobazam and anti-seizure medications, providing insights into its safe and effective use in clinical settings (Gaston et al., 2023).Synergistic effects in epilepsy management: A multicenter study on the cenobamate-clobazam interaction revealed both pharmacokinetic interactions and evidence of synergy, underscoring N-Desmethylclobazam′s potential to enhance treatment outcomes in epilepsy (Osborn and Abou-Khalil, 2023).Analysis of metabolites in forensic science: Research on the measurement of benzodiazepine receptor agonists′ metabolites, including N-Desmethylclobazam, outlined its detection and concentration levels in urine, offering applications in forensic toxicology (Volkova et al., 2023).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany